Senate-Pick Kirk ‘s Insurance, Drug-Industry “Conflicts”

Senate-Pick Kirk ‘s Insurance, Drug-Industry “Conflicts”

Senate-Pick Kirk ‘s Insurance, Drug-Industry “Conflicts”

On Friday, former Democratic National Committee chair Paul Kirk cleared what was probably his last legal hurdle to become the selected-not-elected “temporary senator” from Massachusetts.

A Massachusetts judge, rejecting a Republican challenge, ruled that the veteran Democratic operative was legitimately appointed and could hold his seat until a special election names a permanent successor to the late Senator Edward Kennedy.

The temorary senator’s charge is to fill seat during the Senate debate over health-care reform.

Facebook
Twitter
Email
Flipboard
Pocket

On Friday, former Democratic National Committee chair Paul Kirk cleared what was probably his last legal hurdle to become the selected-not-elected “temporary senator” from Massachusetts.

A Massachusetts judge, rejecting a Republican challenge, ruled that the veteran Democratic operative was legitimately appointed and could hold his seat until a special election names a permanent successor to the late Senator Edward Kennedy.

The temorary senator’s charge is to fill seat during the Senate debate over health-care reform.

Kirk, the choice of the Kennedy family for the temporary position, is a former aide to the late senator and an exceptionally loyal Democrat — who after chairing the DNC helped create the Commission on Presidential Debates that has effectively frozen out third-party contenders for two decades.

But he is something else: An insurance-conglomerate board member who has worked as a lobbyist for the pharmaceutical industry.

Kirk sits on the board of Hartford Financial Services, a massive insurance combine that identifies itself as a “leader in group retiree medical” benefits with “flexibility in designing a plan that integrates with Medicare.”

The Hartford connection has been worth a lot to Kirk who is the firm’s longest-serving independent director. According to a review by the Boston Herald the senator-to-be collected $250,942 in salary and stock awards from the firm last year, along with stock options that extend to 2014.

Kirk has, as well, padded his bankroll with funds earned as a lobbyist for Hoechst Marion Roussel and Aventis, two of the world’s largest pharmaceutical corporations. Kirk reportedly earned $80,000 from those companies.

Should people be concerned about the fact that a man who has been positioned as “the 60th vote” for Democrats seeking health care reform is indebted to insurance and pharmaceutical giants?

Yes, says Public Citizen’s Craig Holman.

“Obviously, this is a conflict of interest and raises serious concerns,” argues the ethics-in-government advocate, who adds that the appointment of Kirk is “distressing” because “there were many qualified people.”

Among those passed over by Massachusetts Governor Deval Patrick in his rush to appoint Kirk — after the state legislature changed the law to permit the selection — was former Massachusetts Governor Michael Dukakis. The Boston Globe had argued for the choice of the 1988 Democratic presidential nominee because of his experience and his reputation for integrity.

Kirk claims that he has “no conflicts,” while at the same time suggesting that he will leave the Hartford board when he begins his four-month “temporary senator” stint.

But Holman argues: “Clearly that’s going to be a temporary resignation with a wink and a nod… Everything he learns in the Senate he is free to profit from.”

Wendell Potter, the former insurance-industry executive who left Cigna in order to blow the whistle on the industry’s profiteering and intensive efforts to influence the health care debate, was incredulous when he was contacted by Boston political reporters:

“Why in the world would they choose someone who has close ties to the insurance industry?” asked Wendell Potter, a former health insurance exec-turned-whistleblower. He noted the health insurance industry has much to gain in the current reform package, especially if coverage is mandated without competition from a government insurance option, as a bill now before the Senate finance committee proposes.

“This would represent an enormous new revenue stream for the insurance industry,” Potter said, adding of Kirk, “On one hand, he certainly would be knowledgeable of insurance issues, and on the other hand… there are going to be questions about his objectivity.”

Appointing senators is always problematic, as the troubles experienced earlier this year in Illinois, New York and other states so amply illustrated.

But Patrick’s decision to appoint a former lobbyist with close ties to an industry that could be redefined by decisions made this fall in the Senate offers what may well be the best illustration yet of why senator’s should be chosen by voters in elections — not by governors and political insiders operating in backrooms.

Thank you for reading The Nation!

We hope you enjoyed the story you just read. It’s just one of many examples of incisive, deeply-reported journalism we publish—journalism that shifts the needle on important issues, uncovers malfeasance and corruption, and uplifts voices and perspectives that often go unheard in mainstream media. For nearly 160 years, The Nation has spoken truth to power and shone a light on issues that would otherwise be swept under the rug.

In a critical election year as well as a time of media austerity, independent journalism needs your continued support. The best way to do this is with a recurring donation. This month, we are asking readers like you who value truth and democracy to step up and support The Nation with a monthly contribution. We call these monthly donors Sustainers, a small but mighty group of supporters who ensure our team of writers, editors, and fact-checkers have the resources they need to report on breaking news, investigative feature stories that often take weeks or months to report, and much more.

There’s a lot to talk about in the coming months, from the presidential election and Supreme Court battles to the fight for bodily autonomy. We’ll cover all these issues and more, but this is only made possible with support from sustaining donors. Donate today—any amount you can spare each month is appreciated, even just the price of a cup of coffee.

The Nation does not bow to the interests of a corporate owner or advertisers—we answer only to readers like you who make our work possible. Set up a recurring donation today and ensure we can continue to hold the powerful accountable.

Thank you for your generosity.

Ad Policy
x